GLP-1 Drugs May Reduce Epilepsy Risk in People with Type 2 Diabetes | Research

The takeaway

Retrospective analysis suggests GLP-1 receptor agonist use is associated with lower epilepsy risk compared to DPP-4 inhibitors in adults with type 2 diabetes.

Lower epilepsy risk with GLP-1 RA
Compared to DPP-4i use in adults with type 2 diabetes

What the researchers found

GLP-1 RA use was associated with lower incident epilepsy risk compared to DPP-4i use in adults with T2DM, providing real-world evidence supporting preclinical neuroprotective findings.

Why it matters

Adding epilepsy prevention to GLP-1 drugs' growing list of neuroprotective benefits strengthens the case for early use in diabetic patients at risk for neurological complications.

How the study worked

Retrospective comparative effectiveness study; GLP-1 RA vs DPP-4i users with T2DM; incident epilepsy as primary outcome.

What this study cannot tell us

Retrospective observational design; potential confounding by indication; epilepsy diagnosis in databases may be imprecise; association doesn't prove causation.

How to read the evidence

Retrospective comparative effectiveness study — provides real-world evidence but cannot establish causation.

When this study was published

Published in 2026, expanding the known neuroprotective associations of GLP-1 drugs.

The bigger picture

This adds to the expanding evidence that GLP-1 drugs protect the brain across multiple conditions — from Alzheimer's to TBI to now potentially epilepsy — suggesting broad neuroprotective mechanisms.

Questions still open

What mechanism might explain GLP-1 drugs' anti-epileptic effect — anti-inflammatory, anti-excitotoxic, or metabolic?
Should GLP-1 drugs be preferred for diabetic patients with seizure risk factors?

Common questions

Can diabetes medications prevent seizures?

This study found that GLP-1 drugs were associated with lower epilepsy risk in diabetic patients compared to another drug class. While not proven as anti-seizure medications, they may have neuroprotective effects that reduce seizure vulnerability.

Why are diabetics at higher risk for epilepsy?

Diabetes can damage the brain through blood sugar fluctuations, inflammation, and vascular disease. These changes can make brain cells more excitable, increasing seizure risk, particularly in older adults.

Read the original research

Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes.

Neurology, 106(1), e214509

View on PubMed ↗Publisher’s paper ↗

Citation

Cheng, Ching-Yang; Lo, Shih-Chang; Huang, Chien-Ning; Yang, Yi-Sun; Wang, Yu-Hsun; Kornelius, Edy. (2026). Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes.. Neurology, 106(1), e214509. https://doi.org/10.1212/WNL.0000000000214509